WELLINGTON, New Zealand, May 20, 2019 /PRNewswire/ -- Research has demonstrated that the use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast Cancer Risk Evaluation Tool improves breast cancer risk stratification and could be used to help guide personalized medicine through risk-adapted screening.
The study, "A case-control study to add volumetric or clinical mammographic density into the Tyrer-Cuzick breast cancer risk model," was published in the May 11 issue of Journal of Breast Imaging (doi.org/10.1093/jbi/wbz006), the official journal of the Society of Breast Imaging.
The paper used visual BI-RADS 4th Edition assessments from breast imaging specialists at the University of Virginia (UVA) and included 474 women who were diagnosed with invasive breast cancer alongside 2,243 controls. The results demonstrated that the addition of volumetric and visual mammographic density measures to classical risk factors improves risk stratification, increasing the number of women accurately identified at high and lower risk of breast cancer. The Tyrer-Cuzick Tool, one of the most complete and widely used risk models, now accepts VolparaDensity volumetric breast density assessment as a validated breast density input in Version 8.
Based on the study results, researchers concluded that risk could be used to guide precision medicine through risk-adapted screening and prevention strategies. Further, they noted in the discussion that "volumetric breast density assessment has some practical advantages because it is fully automated and has excellent agreement with 3D breast MRI."
Dr. Jack Cuzick, John Snow Professor of Epidemiology, Director, Wolfson Institute of Preventive Medicine, and Head, Centre for Cancer Prevention, stated: "Including breast density into risk models makes sense. Breast density is a strong risk factor for breast cancer, and it is largely independent of all other known risk factors. Breast density contributes as much information as all other factors combined, nearly doubling the predictive value of the risk model. Screening programs need to take this into consideration in order to develop a personalized breast care plan for each woman."
Dr. Eric J. Kraemer, Radiologist at Reno Diagnostic Centers, stated: "Incorporating an objective density measure and the Tyrer-Cuzick risk model has allowed us to better personalize screening for all of our patients. Patients with a lifetime risk of greater than 20% are recommended for mammography and MRI screening. The personalized plan for patients with dense breasts but with lower risk includes mammography and automated breast ultrasound (ABUS). For patients that do not have dense breasts and that are at low risk of developing breast cancer, mammography continues to be the gold standard in breast cancer screening. Developing a personalized breast care for each woman depending on her specific risk factors means that we can do a better job at detecting cancer earlier, ensuring that lives are saved."
As one of the clinical applications within VolparaEnterprise, the VolparaDensity clinical application provides radiologists with automated, objective volumetric breast density assessments and a breast density category shown to correlate to BI-RADS 4th and 5th Editions. It is CE-marked and cleared by the FDA, Health Canada, and the TGA.
"VolparaDensity has been in Tyrer-Cuzick for some time now, and the publication of this substantial validation paper is a key link that will assist in further accelerating uptake. This research has now shown that VolparaDensity is about equal to world experts in judging breast density for risk assessment," said Dr Ralph Highnam, CEO of Volpara. "This is particularly relevant as various groups in the United States and globally are moving towards some form of risk-based screening. It is also encouraging to see how important density is in that assessment and the vital role that Volpara can play in helping women receive the right care at the right age."
About Volpara Solutions
Volpara Solutions is the wholly owned sales and marketing arm of Volpara Health Technologies Limited of New Zealand. Available in most markets where breast cancer screening is commonplace, VolparaDensity provides an objective volumetric measure of breast density from both digital mammography and tomosynthesis data. Volpara®Enterprise™ software is a suite of quantitative breast imaging tools for personalized measurements of density, patient-specific x-ray dose, breast compression, breast positioning, and other factors designed to provide critical insight for breast imaging workflow. The Volpara®Live!™ system provides technologists with a real-time decision support at the point of care to assess image quality. For more information, visit www.volparasolutions.com.
SOURCE Volpara Solutions